New Zealand drugs regulator approves use of MDMA to treat severe PTSD
Published

New Zealand decision follows Australian approval in 2023 of psychedelics to treat PTSD and treatment-resistant depression Two psychiatrists in New Zealand won approval on Friday to prescribe pharmaceutical-grade MDMA to people with severe post-traumatic stress disorder (PTSD).
Havoc links to the original reporting. The full story stays with the publisher.